CJC-1295 No DAC + Ipamorelin Blend: Research Overview

Published: June 2026

CJC-1295 No DAC + Ipamorelin Blend: Research Overview

White Market Peptides offers research-grade CJC-1295 No DAC + Ipamorelin (10 mg) at a 99%+ purity standard, third-party tested for identity and purity.

Overview

The CJC-1295 No DAC + Ipamorelin blend is a lyophilized research peptide formulation combining CJC-1295 No DAC (5 mg; also designated Mod GRF 1-29 or Modified GRF(1-29)) and Ipamorelin (5 mg) in a single 10 mg vial. Each component has been characterized independently in the peer-reviewed literature and represents a distinct mechanistic approach to the pituitary GH secretory axis. CJC-1295 No DAC is a DPP-IV–stabilized analog of growth hormone-releasing hormone (GHRH), acting at the GHRH receptor (GHRHR) through the adenylyl cyclase / cAMP / PKA second-messenger pathway. Ipamorelin is a selective synthetic pentapeptide agonist of the ghrelin / growth hormone secretagogue receptor type 1a (GHS-R1a), engaging the phospholipase C / IP₃ / Ca²⁺ pathway.

The research rationale for combining these two compounds is mechanistic: GHRHR and GHS-R1a are distinct receptors expressed on the same anterior pituitary somatotroph cells, and simultaneous stimulation of both pathways produces a supra-additive elevation in GH release compared to either compound alone — a phenomenon originally characterized by Bowers et al. (1990; PMID: 2108187) using earlier GHRP-class secretagogue peptides paired with GHRH in both rodent and human subjects. Combining a stabilized GHRH analog with a selective GHS-R1a agonist in a single formulation provides a well-defined two-component research model for studying dual-pathway GH axis activation.

Note on published pharmacology: The majority of published human pharmacokinetic and pharmacodynamic data for the CJC-1295 scaffold is derived from studies on the with-DAC (Drug Affinity Complex) form — CJC-1295 with DAC (CAS 863971-19-1), which has an extended half-life due to covalent albumin binding. CJC-1295 No DAC (Mod GRF 1-29; CAS 863288-34-0) lacks the DAC moiety and has distinct pharmacokinetics, though the two forms share the same GHRH-receptor agonist mechanism. Researchers should consult literature carefully to distinguish between data on the DAC and No-DAC forms.

Component Molecular Profiles

CJC-1295 No DAC (Mod GRF 1-29)

Ipamorelin

Mechanism of Action

CJC-1295 No DAC: GHRH-Receptor Pathway

CJC-1295 No DAC is an analog of human GHRH(1-29)-NH₂, the N-terminal fragment of hypothalamic GHRH(1-44)-NH₂ that retains full receptor-binding activity. Four amino acid substitutions — D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27 — confer resistance to dipeptidyl peptidase-IV (DPP-IV)–mediated cleavage at the Tyr¹-Ala² bond, the primary enzymatic degradation site for native GHRH(1-29). The result is a DPP-IV–resistant GHRH analog that retains full GHRHR agonism.

Binding of CJC-1295 No DAC to the GHRH receptor (GHRHR), a class B G protein-coupled receptor on pituitary somatotrophs, activates G_αs-coupled adenylyl cyclase, generating cyclic AMP (cAMP) and activating protein kinase A (PKA). PKA-mediated phosphorylation of key transcription factors and ion channels increases intracellular Ca²⁺ and drives exocytosis of GH secretory granules, while also stimulating transcription of the GH gene.

Ipamorelin: GHS-R1a Pathway

Ipamorelin is a selective synthetic agonist of GHS-R1a, the ghrelin receptor. GHS-R1a couples to G_αq, activating phospholipase C (PLC) to generate IP₃ and DAG. IP₃ mobilizes intracellular Ca²⁺ from the endoplasmic reticulum, triggering GH granule exocytosis in the same somatotroph cell through a pathway mechanistically distinct from the cAMP pathway engaged by GHRHR.

Dual-Pathway Supra-Additive GH Release

Because GHRHR and GHS-R1a signal through distinct second-messenger cascades (cAMP/PKA vs. PLC/Ca²⁺), their simultaneous activation produces GH release greater than the sum of either agonist alone — a supra-additive response originally described by Bowers et al. (1990; PMID: 2108187) in rodents and human subjects using GHRH paired with GHRP-class peptides. This mechanistic complementarity is the primary research rationale for formulating a GHRH analog (CJC-1295 No DAC) and a GHS-R1a agonist (ipamorelin) as a combination research tool.

Key Areas of Investigation

GHRH Receptor Pharmacology and DPP-IV Resistance

The enzymatic instability of native GHRH(1-29) — with a plasma half-life of approximately 2 minutes due to DPP-IV cleavage — has motivated substantial interest in DPP-IV–resistant GHRH analogs as research tools for controlled GH-axis stimulation studies. The four-substitution strategy in Mod GRF 1-29 / CJC-1295 No DAC extends the effective half-life to a range more suitable for standard subcutaneous dosing paradigms without altering GHRHR pharmacology. This DPP-IV–stabilized scaffold shares its core receptor-level mechanism with the extensively characterized CJC-1295 with-DAC compound studied by Teichman et al. (2006; PMID: 16352683), which demonstrated sustained dose-dependent GH and IGF-1 stimulation over multi-day intervals in a randomized controlled study, though the DAC form’s prolonged kinetics differ substantially from the No-DAC form.

Dual GH-Axis Stimulation: GHRP + GHRH Combination Models

The foundational characterization of GHRH + GHRP synergy by Bowers et al. (1990; PMID: 2108187) has informed a wide body of preclinical research examining pulsatile GH restoration models. In that study, co-administration of GHRH and GHRP in normal men produced GH release that exceeded the sum of each compound administered alone, consistent with two non-competing second-messenger pathways converging on the same somatotroph population. Subsequent preclinical and early clinical work has used various GHRH-class + GHRP-class pairings to model the GH secretory dynamics of younger or healthier physiological states, with the CJC-1295 No DAC + ipamorelin combination representing a well-characterized instance of this research strategy.

GH/IGF-1 Axis Downstream Endpoints in Preclinical Models

Research using GHRH-analog + GHRP combinations has examined downstream GH/IGF-1 axis responses including serum IGF-1 and IGFBP-3 dynamics, body composition endpoints (muscle cross-sectional area, intramuscular fat, visceral adipose tissue), and GH pulse characteristics (peak amplitude, pulse frequency, trough levels). These endpoints serve as functional readouts of GH-axis stimulation intensity and are used in preclinical systems to distinguish the effects of different GHRH/GHRP dose ratios and pairing strategies.

Looking to source this compound? CJC-1295 No DAC + Ipamorelin (10 mg) is available for laboratory research, with documented batch testing.

Key Published References

1. Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975–982. PMID: 2108187
2. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683 (DAC form; cited for shared GHRHR mechanism)
3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PMID: 9849822

Related Research

For published research on the individual components, see: Ipamorelin Research Overview and Tesamorelin Research Overview (a clinically characterized GHRH analog from the same receptor class).

Product Availability

CJC-1295 No DAC + Ipamorelin (10 mg) is available for qualified research applications through White Market Peptides: CJC-1295 No DAC + Ipamorelin 10 mg: Research Grade.